Advertisement
Journal Home
Search for

Articles in Press

Return to articles in press list

Combination of high frequency oscillatory ventilation and interventional lung assist in severe acute respiratory distress syndrome

Matthias Lubnow, MDaCorresponding Author Informationemail address, Andreas Luchner, MDaemail address, Alois Philippbemail address, Stefan Buchner, MDaemail address, Andreas Jeron, MDaemail address, Christian Karagiannidis, MDaemail address, Thomas Bein, MDcemail address, Michael Pawlik, MDcemail address, Carsten Jungbauer, MDaemail address, Christof Schmid, MDbemail address, Günter A.J. Riegger, MDaemail address, Michael Pfeifer, MDaemail address, Thomas Müller, MDaemail address

published online 15 January 2010.
Corrected Proof

Abstract 

Background

The combination of high-frequency oscillatory ventilation (HFOV) and extracorporeal carbon dioxide removal with the interventional lung assist (iLA) in severe acute respiratory distress syndrome (ARDS) represents a novel treatment option.

Methods

The study used a retrospective single-center analysis of 21 consecutive adult patients with severe ARDS, ventilated with HFOV/iLA. Efficiency, side effects, and outcome of combined treatment are presented as median (interquartile range).

Measurements and main results

The following were used to determine patient characteristics: sequential organ failure assessment score, 14; simplified acute physiology score II, 41; and Murray score, 4. The duration of combined treatment was 6 days. The blood flow through the iLA was 1.9 L/min.

The Pao2/inspired fraction of oxygen ratio increased from 61 (47-86) to 98 (67-116) within 2 hours and to 106 (70-135) mm Hg at 24 hours. Paco2 decreased from 58 (50-76) to 37 (29-47) mm Hg at 2 hours with normalization of pH 7.28 (7.16-7.36) to 7.43 (7.33-7.49) after 2 hours associated with hemodynamic stabilization. In 6 patients, complications due to iLA treatment were observed, and in 3 patients, complications associated with HFOV were seen. Weaning from HFOV/iLA was successful in 10 patients. The 30-day mortality rate was 43%, and hospital mortality rate was 57%.

Conclusion

The combination of HFOV/iLA is an option in severe pulmonary failure if conventional ventilation fails and pumpdriven extracorporeal membrane oxygenation therapy is not available.

a Department of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany

b Department of Cardiothoracic Surgery, University Hospital Regensburg, 93053 Regensburg, Germany

c Department of Anaesthesiology, University Hospital Regensburg, 93053 Regensburg, Germany

Corresponding Author InformationCorresponding author. Tel.: +49 941 944 7350; fax: +49 941 944 7356.

 Competing interests: TB and TM received lecture honorarium from Novalung GmbH, the other authors declared no competing interests.

PII: S0883-9441(09)00281-0

doi:10.1016/j.jcrc.2009.11.004

Advertisement